Telix Pharmaceuticals Limited (TLX)
| Market Cap | 3.13B -5.4% |
| Revenue (ttm) | 890.79M +33.5% |
| Net Income | 33.50M +183.8% |
| EPS | 0.09 +174.8% |
| Shares Out | 339.78M |
| PE Ratio | 98.87 |
| Forward PE | 542.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 110,831 |
| Open | 9.34 |
| Previous Close | 9.36 |
| Day's Range | 9.18 - 9.34 |
| 52-Week Range | 6.28 - 13.11 |
| Beta | 0.63 |
| Analysts | Strong Buy |
| Price Target | 19.90 (+115.6%) |
| Earnings Date | Oct 22, 2026 |
About TLX
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $19.9, which is an increase of 115.60% from the latest price.
News
Profound Medical Reports Strong Third Quarter 2026 Results; Expands U.S. Distribution and Positions Leadership for Next Phase of Growth
Gross margin reaches 78%; cash used in operating activities declines 56% sequentially Profound expects full-year 2026 revenue to be at least $25.0 million; minimum gross margin projection for the year...
Telix Targets $1.5 Bln Revenue In 2027 As ITM Deal May Accelerate Therapy Launch To 2027
(RTTNews) - Telix Pharmaceuticals Ltd. (TLX) is targeting approximately $1.5 billion in revenue in 2027, including the anticipated contribution from its proposed ITM acquisition. In late September, Te...
Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push
Telix Pharmaceuticals NASDAQ: TLX outlined its commercial growth strategy, late-stage radiopharmaceutical pipeline and planned integration of ITM at an investor event in Melbourne, with management emp...
Telix Pharmaceuticals Shares Rebound After October Selloff With Pixclara Launch and ITM Deal in Focus
Telix shares gained almost 3% as investors weighed steady revenue growth, Pixclara's US approval, the planned ITM acquisition and upcoming milestones against risks to future margins.
Telix Pharmaceuticals Transcript: CMD 2026
FY26 revenue is expected near $1bn, with precision medicine growth above 25% YoY. ITM, product launches and late-stage programs support a step-up in 2027, while 2028 is targeted as the start of an earnings-growth phase.
Telix Pharmaceuticals Slides: FY 2026
Telix Pharmaceuticals has posted slides in relation to its FY 2026 quarterly earnings report, which was published on November 3, 2026.
Telix Pharmaceuticals falls -9.9%
Telix Pharmaceuticals (TLX) is down -9.9%, or -$1.10 to $10.06.
Telix Shares Sink Nearly 10% as Investors Shrug Off 19% Revenue Growth and Pixclara Launch in Third Quarter
Telix Pharmaceuticals shares fell sharply after third-quarter revenue growth showed no acceleration, despite strong demand for imaging products and progress in its cancer pipeline.
Telix Pharmaceuticals falls -10.1%
Telix Pharmaceuticals (TLX) is down -10.1%, or -$1.13 to $10.03.
Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance And Advances Pipeline Programs
(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a financial update reflecting a 19% increase in group revenue and key operational highlights for the third quarter en...
Telix Pharmaceuticals Shares Slide 6.6% as Radiopharmaceutical Stock Extends Volatile 2026 Run on the ASX
Telix Pharmaceuticals shares fell 6.6% to A$14.72, extending a volatile period as investors weigh strong revenue growth against rising costs, valuation concerns and regulatory risks.
Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance
(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third quarter ended September 30...
Telix Pharmaceuticals reports Q2 group revenue $245M vs. $206M last year
Christian Behrenbruch, Managing Director and Group CEO, stated, “Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in...
Telix Pharmaceuticals reaffirms FY26 revenue and other income view $1B
Telix reaffirmed that FY26 revenue and other income is expected to be in excess of $1B, with revenue tracking in line with upper end of FY26 guidance of $950M-$970M plus…
Telix Reports Third Quarter 2026 Financial Performance
MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a financial update on its commercial and operational pe...
Telix Pharmaceuticals Earnings release: Q3 2026
Telix Pharmaceuticals released its Q3 2026 earnings on October 20, 2026, summarizing the period's financial results.
Telix, Ekalia enter pact to advance U.S. production of astatine-211
Telix Pharmaceuticals (TLX) and Ekalia, a joint venture between Ion Beam Applications and Framatome, announced a collaboration to advance scalable United States production of astatine-211, an alpha-em...
Ekalia takes an important step in the deployment of Astatine-211 in the United States through a collaboration agreement with Telix
The joint venture between IBA and Framatome will leverage Telix's capabilities to accelerate the production and availability of Astatine-211 in the US market.
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
MELBOURNE, Australia and LOUVAIN-LA-NEUVE, Belgium and PARIS and INDIANAPOLIS, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and Ekalia, a joint vent...
Profound Medical enters co-education agreement with Telix Pharmaceuticals
Profound Medical (PROF) announced it is entering into a co-education agreement with Telix Pharmaceuticals (TLX). The agreement establishes a framework through which the companies intend to educate uro...
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix's PSMA-PET molecular imaging technologies and Profound's MRI-guided TULSA-PRO ® Agreement provides...
Telix Pharmaceuticals’ brain cancer imaging drug applied on first U.S. patients
Telix Pharmaceuticals (TLX) announced that the first patients in the U.S. have been dosed with Pixclara – floretyrosine F 18 or 18F-FET -, its FDA-approved, amino acid positron emission tomography,…
First Patients Dosed with Telix's FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
MELBOURNE, Australia and INDIANAPOLIS, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patients in the United States (U....
IBA and Telix strengthen ties through agreement to distribute ARTMS's QIS®
IBA to offer QUANTM® Irradiation System solid-target technology to cyclotron users worldwide, scaling local production of radiometals for theranostics
Telix Pharmaceuticals Transcript: R&D Day 2026
The event highlighted a robust, late-stage pipeline in prostate, kidney, and brain cancers, with multiple phase III trials and imminent product launches. Strategic partnerships, global expansion, and a theranostic platform support significant market opportunities and operational excellence.